^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Oncomine™ Dx Target Test

    Company:
    Thermo Fisher Scientific
    Related tests:
    15d
    Coverage of Actionable Alterations In Non-Small Cell Lung Cancer by Hybrid Capture-Based FoundationOne®CDx Compared With Amplicon-based Oncomine™ DX. (PubMed, Oncologist)
    In summary, in advanced NSCLC, hybrid capture-based NGS, such as F1CDx, may capture more actionable genomic alterations as compared with ODxTT, an amplicon-based NGS.
    Journal • Tumor mutational burden • MSi-H Biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    KRAS mutation • EGFR mutation • MSI-H/dMMR • KRAS G12C • MET mutation • KRAS G12
    |
    FoundationOne® CDx • Oncomine™ Dx Target Test
    1m
    Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer. (PubMed, Sci Rep)
    Our in-house CGP shows high concordance with ODxTT and serves as a powerful complementary tool. These findings support a strategic testing algorithm where CGP is incorporated for patients with negative or inconclusive ODxTT results, or at the time of recurrence, to maximize opportunities for individualized therapy in resected NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • RET (Ret Proto-Oncogene)
    |
    EGFR mutation • RET fusion
    |
    Oncomine™ Dx Target Test
    4ms
    Utility of ultrasound-guided transbronchial needle biopsy using an acquire needle in the diagnosis of chest and mediastinal diseases. (PubMed, Jpn J Clin Oncol)
    EBUS-TBNB demonstrated high efficacy for diagnosing lung cancer, including PD-L1 testing and NGS, and for obtaining histological core tissue.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Oncomine™ Dx Target Test
    5ms
    Effectiveness of afatinib after long-term gefitinib treatment for EGFR L858R and S768I compound mutation-positive lung adenocarcinoma: A case report. (PubMed, Respir Med Case Rep)
    Furthermore, immunohistochemical analysis revealed an increase in HER2 and HER3 protein expression in the gefitinib-resistant specimens. These findings suggest that HER2 and HER3 upregulation may contribute to gefitinib resistance, and that afatinib may effectively target these resistance mechanisms.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • EGFR L858R • HER-2 expression • EGFR S768I
    |
    Oncomine™ Dx Target Test
    |
    Gilotrif (afatinib) • gefitinib
    5ms
    Stepwise identification of an SQSTM1::NTRK3 fusion in papillary thyroid carcinoma: Diagnostic pitfalls and the value of integrative genomic profiling. (PubMed, Pathol Res Pract)
    This case underscores the importance of integrating histopathology, immunohistochemistry, and RNA-based CGP to identify rare but actionable gene fusions. Moreover, long-term preservation of formalin-fixed paraffin-embedded (FFPE) tissue enabled retrospective genomic testing, particularly when initial panel testing was inconclusive or delayed.
    Journal
    |
    BRAF (B-raf proto-oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • SQSTM1 (Sequestosome 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E
    |
    Oncomine™ Dx Target Test
    5ms
    Suitability of Specimens from Pleural Dissemination of Non-Small Cell Lung Cancer for Genetic Testing Using Forceps and Cryobiopsy. (PubMed, Respiration)
    This exploratory study demonstrates that combining cryobiopsy with forceps biopsy during pleuroscopy improves specimen suitability for genetic analysis, with pleural tumor size emerging as a key determinant factor. Further prospective studies are warranted to validate these findings.
    Journal
    |
    Oncomine™ Dx Target Test
    5ms
    The Genomic Landscape of Romanian Non-Small Cell Lung Cancer Patients: The Insights from Routine NGS Testing with the Oncomine Dx Target Panel at the PATHOS Molecular Pathology Laboratory. (PubMed, Cancers (Basel))
    This study provides the first large-scale molecular snapshot of NSCLC in Romania. While the overall genomic profiles align with Western populations, the higher frequency of KRAS p.G12C and FGFR amplifications highlights the value of region-specific data to support targeted therapies in Eastern Europe.
    Journal • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • FGFR3 (Fibroblast growth factor receptor 3) • EML4 (EMAP Like 4) • FGFR1 (Fibroblast growth factor receptor 1) • KIF5B (Kinesin Family Member 5B) • CCDC6 (Coiled-Coil Domain Containing 6)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • HER-2 amplification • EGFR L858R • EGFR exon 19 deletion • ALK fusion • ALK mutation • KRAS G12
    |
    Oncomine™ Dx Target Test
    6ms
    Neoadjuvant Chemotherapy With Selpercatinib for Locally Advanced RET Fusion-Positive Papillary Thyroid Carcinoma: A Case Report. (PubMed, Case Rep Endocrinol)
    The postoperative course was uneventful, with ongoing follow-up. This case is a successful case of neoadjuvant chemotherapy for RET fusion-positive PTC with local regional progression.
    Journal
    |
    RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
    |
    RET fusion • RET positive
    |
    Oncomine™ Dx Target Test
    |
    Retevmo (selpercatinib)
    6ms
    Suitability of Frozen Pleural Fluid Pellets for Next-Generation Sequencing-Based Driver Gene Testing in Non-Small Cell Lung Cancer. (PubMed, Thorac Cancer)
    Our findings indicate that frozen pleural fluid pellets are suitable for NGS-based driver gene testing in patients with advanced NSCLC. This approach provides a practical alternative for multigene testing when sufficient tissue is not available.
    Observational data • Retrospective data • Journal • Next-generation sequencing
    |
    Oncomine™ Dx Target Test
    7ms
    Sotorasib Is Not Effective in a KRAS-Mutated Patient With Brain Metastases From Lung Adenocarcinoma due to Multiple Gene Co-Mutations. (PubMed, Respirol Case Rep)
    Unexpectedly, however, Sotorasib was ineffective, and the disease progressed. Cancer Genome Profiling (CGP) Test revealed that mutations of p53 and BRCA2 were already present in the patient's primary tumour, resulting in the initial resistance to standard targeted therapy.
    Journal • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset)
    |
    TP53 mutation • KRAS mutation • KRAS G12C • KRAS G12
    |
    Oncomine™ Dx Target Test
    |
    Lumakras (sotorasib)
    8ms
    Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer. (PubMed, Int J Clin Oncol)
    Concordance between IHC and genomic testing in assessing BRAF V600E was encouragingly high; its reliability and potentially short TAT should benefit patients, especially those with ATC.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    FoundationOne® CDx • Oncomine™ Dx Target Test • MEBGEN™ BRAF 3 Kit • MEBGEN™ BRAF Kit
    8ms
    Real-world Data of the Lung Cancer Compact Panel™ in Non-small Cell Lung Cancer Using Tissue Samples. (PubMed, Anticancer Res)
    These findings highlight LCCP's potential to improve personalized treatment strategies for NSCLC.
    Retrospective data • Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion
    |
    Oncomine™ Dx Target Test